What happens now that the FDA rejected ecstasy-assisted therapy for PTSD? Experts weigh inByBruce GilPublishedAugust 13, 2024
A journal retracted three papers on ecstasy-assisted therapy for PTSD due to "unethical conduct"ByBruce GilPublishedAugust 12, 2024
FDA approves nasal spray alternative to EpiPens for allergic reactionsByBruce GilPublishedAugust 12, 2024
The FTC shut down an AI-powered app that claimed it could diagnose STIs from penis picturesByBruce GilUpdatedAugust 12, 2024
A third death is linked to Boar's Head deli meat, as listeria outbreak expandsByBruce GilPublishedAugust 9, 2024
Zepbound sales soar, Ozempic sales miss, and CVS shakes up its leadership: Pharma news round upByBruce GilPublishedAugust 9, 2024
Getting your hands on Zepbound may get easier this year with new single-dose vialsByBruce GilPublishedAugust 8, 2024
Zepbound and Mounjaro sales are so hot Eli Lilly increased its full-year sales outlook by $3 billionByBruce GilPublishedAugust 8, 2024
CVS just split with its insurance boss and hit the gas on AI to cut costsByBruce GilPublishedAugust 7, 2024
The EPA just issued an emergency order on a weedkiller that may be harmful to unborn babiesByBruce GilPublishedAugust 6, 2024
One type of stock that didn't see huge losses today: Weight loss drug makersByBruce GilPublishedAugust 5, 2024
Zepbound is back on the shelves — but shortage isn't over yet, FDA saysByBruce GilPublishedAugust 5, 2024
